Bobby W. Sandage Jr.

Bobby has almost 40 years in the pharmaceutical and venture capital business. He is currently Managing Director of Paula and Rodger Riney Foundation, General Partner in Cultivation Capital Life Sciences Fund II and President and CEO of Euclises Pharmaceuticals. He was formerly President and CEO of Coronado Biosciences (NASDAQ: CNDO) where he led the effort to take the company public, prior to that he was VP of oncology at Covidien Pharmaceuticals (now Mallinckrodt), and prior to that he was the executive vice president, research and development, and Chief Scientific Officer at Indevus Pharmaceuticals (NASDAQ: IDEV). He previously held senior drug development positions at DuPont Merck Pharmaceutical Company and Merrell Dow Pharmaceuticals. He serves on the boards of Immunophotonics, Endevica Biosciences and BioVentures. He received his Ph.D. in clinical pharmacy from Purdue University and his B.S. in pharmacy from the University of Arkansas.